Investigators analyzed hematopoietic reconstitution in 53 patients treated with lentiviral-HSC-gene therapy for diverse conditions such as metachromatic leukodystrophy2,3, Wiskott-Aldrich syndrome4,5, and β-thalassemia6 over a follow-up period of up to eight years, using vector integration sites as markers of clonal identity.
[Nature]